Integer Announces Conference Call to Discuss Third Quarter 2025 Results

Integer Holdings Corporation (NYSE: ITGR) has announced a conference call scheduled for October 23, 2025, at 8 a.m. CT (9 a.m. ET) to discuss its financial results and key business highlights for the third quarter ending September 26, 2025. The company will issue a press release containing its financial results prior to the call, providing investors with crucial data to assess its performance.

During the conference call, management is expected to discuss not only the quarterly financials but also other forward-looking aspects and significant developments within the company. Stakeholders can participate in the call by dialing the domestic number (800) 715-9871 or the international number (646) 307-1963, using Conference ID 3120125 for access.

For those unable to join the live call, an audio replay will be available for seven days. This can be accessed by calling (800) 770-2030 or (609) 800-9909 and entering the same Conference ID. Additionally, the call will be available for live listening and archived replay on the Investor Relations section of Integer’s website at investor.integer.net.

Integer Holdings Corporation stands as a leader in the medical device contract development and manufacturing industry, specifically serving cardiac rhythm management, neuromodulation, and vascular markets. With brands like Greatbatch Medical® and Lake Region Medical®, Integer is dedicated to enhancing patient lives by offering innovative and quality-driven products and solutions.

Investors looking to stay updated on Integer's financial news can easily subscribe for email alerts through the company's Investor Relations webpage. For further inquiries, investor relations can be reached via Kristen Stewart or for media inquiries, Lauren Ban is available. More information about Integer is accessible at www.integer.net.

Integer Holdings Corporation (NYSE: ITGR) is set to conduct a third-quarter results conference call on October 23, 2025, at 8 a.m. CT/9 a.m. ET. As one of the leading medical device contract development and manufacturing organizations, its developments are crucial for investors interested in the dynamic healthcare sector.

When analyzing Integer’s impending financial results, it's vital to consider the broader economic and industry conditions. Given the ongoing advancements in the medical technology space, especially in areas like cardiac rhythm management and neuromodulation, Integer's revenue growth potential is noteworthy. Investors should pay particular attention to the company's ability to innovate and maintain strong partnerships with medical device companies and OEMs.

Notably, the market's response to Integer's previous quarterly results and management commentary can offer insights into how analysts and investors view the company. If Integer reports strong sales and positive earnings trends, this could indicate robust demand for its products, which might lead to upward revisions in earnings estimates. In contrast, revenue misses or cautious guidance may raise red flags about market conditions or operational challenges.

Also, pay attention to updated forecasts for the medical device industry, particularly amid regulatory changes or technological disruptions. Integer's strategic initiatives in cost management and R&D investment could signal its long-term sustainability and competitive positioning, essential factors for prospective investors.

For a comprehensive market perspective, monitor the stock's performance ahead of and following the conference call. Volatility may spike, suggesting a trading opportunity for short-term investors. Longer-term shareholders should evaluate the company’s strategic direction and the potential for sustained growth in its service markets.

In summary, the upcoming conference call is not just a numerical update but a lens into Integer's future prospects. Investors should prepare by considering both the financial data and the qualitative indicators of market strength.